Information Provided By:
Fly News Breaks for July 11, 2017
ALNY
Jul 11, 2017 | 08:56 EDT
BMO Capital analyst Do Kim says that the weakness of Alnylam's stock was caused by increases in ALT associated with the company's fitusiran drug. But the analyst says that such increases are "transient and asymptomatic," and Kim believes that the drug is superior to competing products. Kim recommends buying the stock on weakness.
News For ALNY From the Last 2 Days
There are no results for your query ALNY